Using a state-of-the-art DNA sequencing technique, UA researchers have discovered genetic mutations underlying seizure disorders in previously undiagnosed childrenContinue reading
Category Archives: BioScience
UA Research Suggests Link Between Elevated Blood Sugar, Alzheimer’s Risk
About 5 percent of men and women, ages 65 to 74, have Alzheimer’s disease, and it is estimated that nearly half of those age 85 and older may have the disease. Among known risks are age and geneticsContinue reading
Calimmune an example of Bioscience That Will Blow your Mind
Milken Institute Video from the Global Conference 2013 highlights thought leaders, breakthroughs, and what needs to come next.Continue reading
2013 EY Beyond Borders Report for the Life Science Industry
The business climate for the biotechnology industry remains challenging. In today’s “new normal,” venture capitalists are more selective, IPOs more elusive and alliance partners more demanding. And even as biotech companies grapple with these challenges, health care systems are undergoing a fundamental shift toward outcomes and pay-for-performance.
How is the industry dealing with the twin challenges of boosting operating efficiency and demonstrating economic value?
Are “HOLNets” gaining traction and making R&D more efficient?
What are companies doing differently to collect data and demonstrate the economic value of their products?
Ernst & Young’s Beyond Borders offers insights on these questions and more.
Want to learn more?
Contact Phil Howard and the E&Y Life Sciences Team
in Phoenix at (602) 322-3000.
BIOTECH INVESTING Milestones in Drug Development
Info graphic highlights the key steps for investors to watch in the drug development process. Continue reading
Phase III Colon Cancer Prevention Therapy Trial Now Open for Enrollment
Cancer Prevention Pharmaceuticals, Inc., (CPP) announced today the launch of a Phase III colon cancer prevention trial in collaboration with the National Cancer Institute (NCI) and SWOG, an NCI-supported clinical trials group. The Preventing Adenomas of the Colon with Eflornithine and Sulindac (PACES) trial is a Phase III trial testing CPP’s prevention therapy product CPP-1X/sul (eflornithine/sulindac) in 1340 colon cancer survivors—each of whom will receive daily treatment for three years to prevent the recurrence of cancer or high-risk polyps.Continue reading
Virtual Clinic Showcases New Technology for Teaching Medical Students
The state-of-the-art center at the UA College of Medicine-Phoenix allows students to develop diagnostic skills and patient care abilitiesContinue reading
UA Robotics Surgery Brings Hope to Patients with Mesothelioma
UA Performs World’s First and Second Robot-Assisted Surgeries for MesotheliomaContinue reading
Welcome (Again) To Guayule
It’s common knowledge that America’s largest import is oil, but do you know what’s second? Hint: it’s a commodity used for tires, hoses and thousands of household products.Continue reading